SNPs to Risk of Metastasis (SToRM)
Contact: David Cox, M.S., Ph.D.
| Number of Enrolled Cancer Patients/Survivors: | 1,000 |
|---|---|
| Years of Diagnoses of Enrolled Cancer Patients/Survivors: | N/A |
| Approximate Years of Follow-up: | N/A |
| Cancer Sites Represented: | Metastatic Breast Cancers |
| Biological Specimens Collected: |
Blood/Blood Fraction Germline DNA |
| Treatment Outcome Measures: |
Physician/Medical Record Reported
|
| Co-morbidities at Study Entry: | None |
| Lifestyle Factors: |
Smoking Alcohol Use Physical Activity Body Mass Index Other |
| Treatment Data: |
Surgery Radiation Chemotherapy Hormonal Therapy |
| Treatment Data Assessed By: |
Chart Abstraction Other |
| Is the study open to collaboration? | Yes |
| Additional Information: | We are currently recruiting patients into a French nationwide clinical study of metastatic breast cancer. Cases are included within 12 months of diagnosis of the metastasis, with medical history recorded via questionnaires filled out by the oncologist. 130 patients have been included since May 2013, and we aim to include 1000 patients by May 2015. The main aim of the study is to test genetic susceptibility to metastatic progression, with secondary aims to investigate survival after metastasis. Buffy coats, plasma, and erythrocytes will be available for all subjects. We will also work to identify patients that have archived primary tumor blocks and metastatic biopsies available for subsequent analyses if possible. Our study is registered with clinicaltrials.gov (identifier NCT01460186). |